<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575899</url>
  </required_header>
  <id_info>
    <org_study_id>IRB096-28</org_study_id>
    <nct_id>NCT01575899</nct_id>
  </id_info>
  <brief_title>Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori</brief_title>
  <official_title>Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective controlled randomized open-label clinical trial is designed to determine the
      eradication rate of 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole regimen
      compared with 7-day standard triple therapy for adults infected with Helicobacter pylori in
      Eastern Taiwan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      The resistance rate of Helicobacter pylori (Hp) to amoxicillin and metronidazole therapy is
      significantly higher in Eastern Taiwan as compared to national and worldwide rates. The high
      resistance rate in this territory justified a search for a better eradication regimen for Hp
      infection.

      AIM:

      To evaluate the efficacy and tolerability of a combination therapeutic regimen of
      levofloxacin, amoxicillin/clavulanate and rabeprazole (LAcR) versus a conventional seven-day
      triple therapy with clarithromycin, amoxicillin and rabeprazole (CAR) for the eradication of
      Hp infection.

      METHODS:

      We conducted a open-labeled, prospective, randomized, controlled study in a large tertiary
      referral hospital in Eastern Taiwan. Hp-positive therapy-na√Øve patients with a positive CLO
      test as proven by gastroscopy were recruited for potential random assignment to two 7-day
      treatment groups: LAcR or CAR (control). The primary end point of this study was to evaluate
      the eradication rate of LAcR regimen. Hp eradication was assessed using the 13C-urea breath
      test or CLO test performed at least 4 weeks after end of treatment. Compliance and adverse
      effects with therapy were determined by phone call or outpatient clinic follow up.

      EXPECTED RESULT:

      The seven-day LAcR regimen evaluated in this study provided improved Hp eradication efficacy
      when compared with the traditional seven-day triple therapy in Eastern Taiwan.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early termination due to efficacy
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication Rate (Participants Naive to Anti-H. Pylori Treatment)</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>A negative post-treatment 13C-urea breath test or CLO test result at more than 4 weeks after complete use of drug for treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication Rate of Participants Living in Rural Area.</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>Subgroup analysis on eradication rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after treatment) according to resident area of participants, especially who are living in rural area.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Re-eradication Rate</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>Re-eradication successful rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after the 2nd treatment) with 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Levofloxacin-Amoxicillin/clavulanate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin-Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin-Amox/clav.</intervention_name>
    <description>Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.</description>
    <arm_group_label>Levofloxacin-Amoxicillin/clavulanate</arm_group_label>
    <other_name>Levofloxacin(Cravit), Amoxicillin/clavulanate(Augmentin) and</other_name>
    <other_name>Rabeprazole(Pariet) for 7 days.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin-Amoxicillin</intervention_name>
    <description>Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.</description>
    <arm_group_label>Clarithromycin-Amoxicillin</arm_group_label>
    <other_name>Clarithromycin(Klaricid), Amoxicillin(Hiconcil) and</other_name>
    <other_name>Rabeprazole(Pariet) for 7 days.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient proved with infection of H. pylori in gastric mucosa

          -  Patient with signed informed consent.

        Exclusion Criteria:

          -  woman in breast feeding or pregnancy.

          -  allergy or severe adverse effects to drugs used in study.

          -  severe complications of peptic ulcer disease (like perforation or obstruction).

          -  patients with history of cancer or failure of major organs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Cheh CHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>April 19, 2012</results_first_submitted>
  <results_first_submitted_qc>July 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>July 28, 2012</last_update_submitted>
  <last_update_submitted_qc>July 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Cheh Chen</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Levofloxacin</keyword>
  <keyword>Amoxicillin/clavulanate</keyword>
  <keyword>Rabeprazole</keyword>
  <keyword>Eastern Taiwan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We included H. pylori-positive adult patients assessed by the rapid urease test and histology during the period December 2007 to December 2009 from the out-patient clinic of a single medical center located at Hualien, Eastern Taiwan.</recruitment_details>
      <pre_assignment_details>We excluded patients under the age of 20, woman in pregnancy or breast feeding, those with concomitant illness or conditions (i.e., cardiopulmonary, hepatic, renal diseases, neoplastic diseases), those with severe complication of peptic ulcer disease, like obstruction or perforation, those with allergy to any of the drugs used.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Levofloxacin-Amox/Clav.</title>
          <description>7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.</description>
        </group>
        <group group_id="P2">
          <title>Clarithromycin-Amoxicillin</title>
          <description>7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.</description>
        </group>
        <group group_id="P3">
          <title>Levofloxacin-Amox/Clav. (Re-eradication)</title>
          <description>7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for re-eradication of patient still with evidence of Hp infection after previous intent of eradication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="62">Included patients still with Hp infection after previous therapy without levofloxacin and Augmentin.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levofloxacin-Amox/Clav.</title>
          <description>7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.</description>
        </group>
        <group group_id="B2">
          <title>Clarithromycin-Amoxicillin</title>
          <description>7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.</description>
        </group>
        <group group_id="B3">
          <title>Levofloxacin-Amox/Clav. (Re-eradication)</title>
          <description>7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for re-eradication of patient still with evidence of Hp infection after previous intent of eradication.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.82" spread="12.08"/>
                    <measurement group_id="B2" value="54.63" spread="14.42"/>
                    <measurement group_id="B3" value="54.68" spread="11.81"/>
                    <measurement group_id="B4" value="54.01" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 54 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=54 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Resident area</title>
          <description>Comparison about resident area of participants, living in urban area or rural area.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Urban area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rural area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endoscopic finding</title>
          <description>Comparison between participant's endoscopic finding with or without peptic ulcer disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With peptic ulcer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without peptic ulcer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follow up method</title>
          <description>Information about the follow up method to confirmed the post-treatment Hp status of participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>C13-UBT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLO test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eradication Rate (Participants Naive to Anti-H. Pylori Treatment)</title>
        <description>A negative post-treatment 13C-urea breath test or CLO test result at more than 4 weeks after complete use of drug for treatment.</description>
        <time_frame>4 weeks after complete use of drug for treatment</time_frame>
        <population>Intent to treat analysis of eradication (negative result of follow up method) measured 4 weeks after complete the treatment, for participants never received anti-H. pylori treatment before.</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin-Amox/Clav.</title>
            <description>7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin-Amoxicillin</title>
            <description>7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication Rate (Participants Naive to Anti-H. Pylori Treatment)</title>
          <description>A negative post-treatment 13C-urea breath test or CLO test result at more than 4 weeks after complete use of drug for treatment.</description>
          <population>Intent to treat analysis of eradication (negative result of follow up method) measured 4 weeks after complete the treatment, for participants never received anti-H. pylori treatment before.</population>
          <units>percentage of eradicated participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.1"/>
                    <measurement group_id="O2" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.629</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1526</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Re-eradication Rate</title>
        <description>Re-eradication successful rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after the 2nd treatment) with 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin.</description>
        <time_frame>4 weeks after complete use of drug for treatment</time_frame>
        <population>This intent-to treat analysis is without control group, including patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin.</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin-Amox/Clav. (Re-eradication)</title>
            <description>7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin.</description>
          </group>
        </group_list>
        <measure>
          <title>Re-eradication Rate</title>
          <description>Re-eradication successful rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after the 2nd treatment) with 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin.</description>
          <population>This intent-to treat analysis is without control group, including patients still with Hp infection previously treated with regimen without levofloxacin and Augmentin.</population>
          <units>percentage of successful re-eradication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eradication Rate of Participants Living in Rural Area.</title>
        <description>Subgroup analysis on eradication rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after treatment) according to resident area of participants, especially who are living in rural area.</description>
        <time_frame>4 weeks after complete use of drug for treatment</time_frame>
        <population>Subgroup analysis (intent-to-treat) on eradication rate of participants who are living in rural area of Taiwan.</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin-Amox/Clav.</title>
            <description>Participants who are living in rural area and received 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for Hp eradication.</description>
          </group>
          <group group_id="O2">
            <title>Clarithromycin-Amoxicillin</title>
            <description>Participants who are living in rural area and received 7-day clarithromycin, amoxicillin and rabeprazole for Hp eradication.</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication Rate of Participants Living in Rural Area.</title>
          <description>Subgroup analysis on eradication rate (percentage of participants with a negative result of C13 or CLO test at least four weeks after treatment) according to resident area of participants, especially who are living in rural area.</description>
          <population>Subgroup analysis (intent-to-treat) on eradication rate of participants who are living in rural area of Taiwan.</population>
          <units>percentage of eradicated participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.2589</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>10.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Since participants enrolled into the study till completed the follow up, at least five weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levofloxacin-Amox/Clav.</title>
          <description>7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.</description>
        </group>
        <group group_id="E2">
          <title>Clarithromycin-Amoxicillin</title>
          <description>7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.</description>
        </group>
        <group group_id="E3">
          <title>Levofloxacin-Amox/Clav. (Re-eradication)</title>
          <description>7-day levofloxacin, amoxicillin/clavulanate and rabeprazole for re-eradication of patient still with evidence of Hp infection after previous intent of eradication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Visited our emergency room</sub_title>
                <description>Vomiting during eradication, visited our ER, improved after symptomatic treatment, then the case was loss in follow up.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea / Hiccough</sub_title>
                <description>Hiccough and/or sensation of nausea</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Loose stool / Diarrhea</sub_title>
                <description>Diarrhea or loose stool passage.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Change in appetite / Bitter sensation</sub_title>
                <description>Bitter sensation in tongue, change in taste or appetite.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal fullness / Flatus</sub_title>
                <description>Flatus, abdominal fullness and gas passage.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Poor sleep.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of this study is the local primary resistance of Hp to levofloxacin and to amoxicillin/clavulanate is unknown. We are currently engaged in an on-going investigation of the influence of CYP2C19 genotypes on this new regimen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ming-Cheh, Chen</name_or_title>
      <organization>Buddhist Tzu Chi General Hospital</organization>
      <phone>+886-910-521003</phone>
      <email>MingCheh_chen@tzuchi.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

